{
    "clinical_study": {
        "@rank": "1315", 
        "arm_group": {
            "arm_group_label": "ProOxy, Effects and Side Effects in treating acne", 
            "arm_group_type": "Experimental", 
            "description": "Patients are instructed to clean the face with ProOxy facial cleanser and then spray on the face wet enough but not dripping twice daily (upon waking up and before bedtime) for 3 months."
        }, 
        "brief_summary": {
            "textblock": "This study was conducted to determine the effects and side effects of ProOxy facial spray in\n      the treatment of acne."
        }, 
        "brief_title": "Clinical Trial on the Effects and Side Effects of ProOxy in the Treatment of Acne", 
        "completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "condition": "Acne Vulgaris", 
        "condition_browse": {
            "mesh_term": "Acne Vulgaris"
        }, 
        "detailed_description": {
            "textblock": "A study on the effects and side effects of ProOxy facial spray was done. Sixty people were\n      selected and approved to participate in this study. Pictures of the face (frontal,left side\n      and right side) were taken upon acceptance, during and after treatment at 4,8 and 12 weeks\n      intervals."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients with acne on their faces only\n\n          -  patients who are at least 18 years of age\n\n          -  patients who have normal and disease free skin at the dorsal surface of the   upper\n             arm.\n\n          -  patients who are willing to follow instructions on both the Patch Test Part one and\n             Part Two procedures and to follow scheduled visits.\n\n        Exclusion Criteria\n\n          -  patients with systemic illnesses(such as but not limited to heart disease,\n             hypertension, diabetes, cancer, liver disease, kidney disease)\n\n          -  patients with very dark skin color, Fitzpatrick skin type V-VI, who are prone to\n             post=inflammatory hyperpigmentation.\n\n          -  patients with intake of oral medications including glucocorticoids or any\n             immuno-suppressants or who have undergone ultraviolet phototherapy for the past 2\n             weeks prior to the patch test.\n\n          -  patients with history of contact dermatitis, dermatographism or anaphylaxis.\n\n          -  patients with history of eczematous and inflammatory dermatitis, seborrheic\n             dermatitis and psoriasis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682200", 
            "org_study_id": "PaspaPharma-04"
        }, 
        "intervention": {
            "arm_group_label": "ProOxy, Effects and Side Effects in treating acne", 
            "description": "Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.", 
            "intervention_name": "ProOxy", 
            "intervention_type": "Drug", 
            "other_name": "15% Oxygen solution spray"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "moderate", 
            "facial acne", 
            "acne vulgaris"
        ], 
        "lastchanged_date": "September 7, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Manila", 
                        "country": "Philippines", 
                        "state": "Metro Manila"
                    }, 
                    "name": "Mary Chile General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quezon City", 
                        "country": "Philippines", 
                        "state": "Metro Manila"
                    }, 
                    "name": "Far Eastern University Hospital, Dept of Family Medicine"
                }
            }
        ], 
        "location_countries": {
            "country": "Philippines"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Pilot Clinical Trial on the Efficacy and Safety of ProOxy Facial Spray (Topical 15% Oxygen Solution) in the Treatment of Moderate Facial Acne Vulgaris Among Filipino Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Philippines: Food and Drug Administration (Formerly Known as Bureau of Food and Drugs)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Upon acceptance,pictures are taken and acne lesions are identified and counted and after 4,8, and 12 weeks during and after application of ProOxy.", 
            "measure": "Changes in the appearances,sizes of the acne lesions as well as the disappearance of acne on the face.", 
            "safety_issue": "No", 
            "time_frame": "4,8,12 weeks post application of the spray"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682200"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Medivet Pty Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medivet Pty Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2009", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}